Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Asthma is a common long-term condition that can cause coughing, wheezing, chest tightness and breathlessness. There is uncertainty in the management of acute asthma, with major differences between the management of children and adults. Adults are given magnesium intravenously (into a vein) early in the treatment of an acute asthma attack, but this is not recommended in children. Although magnesium is very safe when given intravenously, there is a need to monitor blood levels. A recent study in adults has demonstrated a good effect for magnesium given via a nebuliser (a machine that delivers medication by turning it into a mist to be inhaled through a face mask or mouthpiece). The aim of this study is to determine whether nebulised magnesium is useful in the treatment of acute asthma in childhood. Currently, the next step in the guidelines would be to commence intravenous treatment with medication to dilate (open up) the airways. If children respond to nebulised magnesium at this stage they may not need to go on to have a canula (needle) placed in the vein for more intensive treatment.

Who can participate?
Children aged 2-16 with severe acute asthma

What does the study involve?
When the child attends either a hospital emergency department or an emergency paediatric unit, if they do not respond to the standard treatment in the first 20 minutes, then they are randomly allocated to receive nebulised salbutamol and ipratropium bromide mixed with either magnesium sulphate or saline (dummy drug) on three occasions at 20-minute intervals. They are closely monitored over the following four hours.

What are the possible benefits and risks of participating?
There are few side effects from magnesium, none described for inhaled magnesium, but these will be monitored by an independent committee.

Where is the study run from?
University Hospital of Wales (UK)

When is the study starting and how long is it expected to run for?
December 2007 to November 2010

Who is funding the study?
Health Technology Assessment Programme (UK)

Who is the main contact?
Dr Colin Powell

Trial website

Contact information



Primary contact

Dr Colin Powell


Contact details

Department of Paediatrics
University Hospital of Wales
Heath Park
CF14 4XW
United Kingdom
+44 (0)29 2074 7747

Additional identifiers

EudraCT number number

Protocol/serial number

HTA 05/503/10

Study information

Scientific title

A randomised, placebo-controlled study of nebulised magnesium in acute severe asthma in children



Study hypothesis

Does nebulised magnesium used as an adjunct to nebulised salbutamol and ipratropium bromide for one hour in children with severe asthma result in a clinical improvement when compared to nebulsied salbutamol, ipratropium bromide and placebo?

More details can be found at:
Protocol can be found at:

Ethics approval

North West Research Ethics Committee, 18/02/2008, ref: 07/H1010/101

Study design

Multicentre randomised placebo-controlled study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Severe exacerbation of asthma


Children aged 2 - 5 years will be randomised to receive nebulised salbutamol 2.5 mg and ipratropium bromide 0.25 mg mixed with either 2.5 ml of isotonic magnesium sulphate (250 mmol/L, tonicity 289 mOsm; 151 mg per dose) or 2.5 ml of isotonic saline on three occasions at twenty-minute intervals. Children 6 years and over will receive 5 mg of nebulised salbutamol.

Total duration of follow-up is one month.

Intervention type



Not Applicable

Drug names

Magnesium, salbutamol, ipratropium bromide

Primary outcome measure

The Yung Asthma Severity Score (ASS) after 60 minutes of treatment

Secondary outcome measures

Clinical (during hospitalisation):
1. ‘Stepping down’ of treatment at one hour i.e. changed to having hourly treatment after the initial three, twenty-minute nebulisers
2. Number and frequency of additional salbutamol
3. Length of stay in hospital
4. Requirement for intravenous bronchodilator treatment
5. Intubation and/or admission to a Paediatric Intensive Care Unit (PICU)

Patient outcomes at follow-up (1 month):
1. Paediatric Quality of Life Inventory (PedsQL™) asthma module parental report for all children and self-completion if aged over 5 years, European Quality of Life questionnaire (EQ-5D)
2. Time off school/nursery
3. Health care resource usage (e.g. General Practitioner [GP] visits, additional prescribing)

Parent outcomes at follow-up (1 month):
1. Time off work (related to child’s illness)

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

For children 6 years and older severe asthma is based on at least one of the following criteria being met:
1. Oxygen saturations less than 92% while breathing room air
2. Too breathless to talk
3. Heart rate greater than 120/min
4. Respiratory rate greater than 30/min
5. Use of accessory neck muscles

For children aged 2 - 5 years of age, severe asthma is based on at least one of the following criteria being met:
1. Oxygen saturations less than 92% while breathing room air
2. Too breathless to talk
3. Heart rate greater than 130/min
4. Respiratory rate greater than 50/min
5. Use of accessory neck muscles

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Coexisting respiratory disease such as cystic fibrosis, chronic lung disease of prematurity
2. Severe renal disease
3. Severe liver disease
4. Known to be pregnant
5. Known to have had a reaction to magnesium previously
6. Parents who are unable to give informed consent
7. Previously randomised into MAGNETIC trial
8. Patients who present with life threatening symptoms
9. Previously involved with a trial of a medicinal product in the three months preceding screening

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

University Hospital of Wales
CF14 4XW
United Kingdom

Sponsor information


Cardiff University (UK)

Sponsor details

Newport Road
CF24 0DE
United Kingdom
+44 (0)29 2087 9274

Sponsor type




Funder type


Funder name

Health Technology Assessment Programme

Alternative name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2013 results in:
2013 results in:
2016 results in

Publication citations

  1. Results

    Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson P, , Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial., Lancet Respir Med, 2013, 1, 4, 301-308, doi: 10.1016/S2213-2600(13)70037-7.

  2. Results

    Powell CV, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson PR, , MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children., Health Technol Assess, 2013, 17, 45, v-vi, 1-216, doi: 10.3310/hta17450.

Additional files

Editorial Notes

24/07/2019: The overall trial end date has been changed from 30/11/2010 to 25/10/2011. 29/12/2016: Publication reference added. 11/05/2009: the following changes were made to the trial record: 1. The overall trial start and end dates were changed from 01/03/2008 and 01/03/2010 to 01/12/2007 and 30/11/2010, respectively. 2. The HTA grant number has been changed from HTA 02/503/10 to HTA 05/503/10.